These observations led to an interesting development bifurcation : Melanotan I (Afamelanotide) continued as a skin peptide and in 2014 received approval as Scenesse for erythropoietic protoporphyria (a rare genetic disease with severe photosensitivity) Melanotan II was abandoned as a cutaneous drug PT-141 / Bremelanotide , a fragment of Melanotan II targeted at MC4R, was developed as a sexual stimulant and in 2019 approved as Vyleesi for hypoactive sexual desire disorder in women (HSDD) Second life in research and the cosmetic underground Melanotan II never reached commercial approval as a drug, but in the research community and cosmetic underground it became well known
Hormonal imbalances can make it much harder to lose weight, especially around the belly
Periodic B12 checks may be considered, especially if anemia, numbness, tingling, or nerve symptoms develop
They often tell me with a smile, I can walk to your office without stopping, or I can play with my grandkids again. If you have obesity, dont wait until you develop other medical conditions to seek treatment
Lance VA, Murphy WA, Sueiras-Diaz J, Coy DH